Partner Organisations

PSI is one of many organisations that are rooted within statistics and data analytics.  As such, we believe that it is important for us to link with other appropriate organisations.

PSI is the association located in the UK for statisticians in the pharmaceutical industry, and therefore we have two representatives on the European Federation of Statisticians in the Pharmaceutical Industry council.  EFSPI brings together representatives of statistical associations within Europe.

PSI has a joint award for Statistical Excellence within the Pharmaceutical Industry with the RSS.  There are six-monthly meetings between representatives of both organisations to maintain good communication and identify opportunities to work together.

Recently PSI has linked with the Indian Association for Statistics in Clinical Trials (IASCT) and members of IASCT can join PSI at a reduced rate. PSI also welcomes members from any other countries, and from statisticians working in the wider clinical research and healthcare industries.

PSI has representatives on the Council of Biopharmaceutical Statisticians.

The Special Interest Groups include suitable representatives from, and interacts with, other organisations depending on the SIG topic.  For instance, the Data Transparency SIG has had discussions with PhUSE members.

The PSI Careers and Academic Liaison Committee (CALC) promotes careers for statisticians and programmers within the pharmaceutical industry, and provides information and insights for those who might want to consider such a career through school and university activities, establishing links with relevant professional groups and via our Careers and Schools/Education websites.

The PSI Regulatory Committee is a joint PSI/EFSPI Committee which aims to provide an industry viewpoint on regulatory issues linked to statistics. This includes promoting best practice, reviewing and collating comments on regulatory policy and guidelines, driving debate on future guidance, and engaging with statisticians in European regulatory agencies, including the EMA Biostatistics Working Party (BSWP), as well as the statistical assessors at the Medicines & Healthcare products Regulatory Agency (MHRA).

PSI recognises that it is part of a wide community and therefore actively engages with the community.



Upcoming Events

Visualising the drug harm profile in Randomised Controlled Trials – A Consensus of UK trial researchers

The UKCRC CTU statisticians’ operations group in collaboration with Imperial College London are hosting a one-day consensus meeting to develop recommendations to support researchers in their choice of visualisations for adverse event data in RCT publications.

PSI Webinar: How can PSI, “a community dedicated to leading and promoting the use of statistics within the healthcare industries for the benefit of patients”, help you be more successful in your career?

Have you ever wondered what it takes to be successful as a statistician or data scientist in the healthcare/pharma industry and what can give you the extra edge to develop your career? Come and listen to these industry leaders views on how to be successful and the advantages of being part of the PSI community.

PSI Journal Club: Progressing Phase II Data into Phase III

Our next journal club features two papers on the topic of Progressing Phase II Data into Phase III, held on the 23rd April 2020 from 4-5pm BST. Please join us to hear Haolun Shi (Simon Fraser University, Burnaby) and Daniele De Martini (Università degli Studi di Milano‐Bicocca, Milan) present their recent work. The webinar will be chaired by Andy Grieve (UCB).

Introduction To Industry Training Course 2020

The ITIT course will take 25 delegates new to the industry on a complete drug development experience from discovery to marketing. They will visit 6 companies from October 2020 to July 2021 to learn about 6 topics from experts in their field. The ITIT course will have 3 sessions in continental Europe and 3 - 4 sessions in the UK. It promises to be a truly memorable course.

A PSI Training Course - R for SAS Users

This course is aimed at Statisticians and Programmers experienced in SAS, but little or no experience with R. An Introduction to R studio and the R language, statistical graphics, programming statistical models, simulations and more…

PSI Toxicology SIG Workshop

PSI Toxicology SIG workshop – 24th and 25th November 2020 The Toxicology SIG provides a forum for statisticians working in regulatory/investigative toxicology, as well as most other pre-clinical areas, to discuss issues and interact with one another. This 1.5-day workshop will involve approximately 20 statisticians, focusing on discussions around “best practice” in the statistical analysis of various data types. The afternoon of Day 1 will include a 4.5 hour Bayesian training course focused towards applications in toxicology/pre-clinical, provided by Prof. Dr. Katja Ickstadt and is included in the workshop fee. The cost will be £270 including VAT per delegate, inclusive of food and one night’s accommodation (and the training course). The workshop is being held at the Crowne Plaza Hotel, Heathrow. The agenda and topics that will be discussed are yet to be finalised, but please get in touch with gareth.thomas@covance.com if you have suggestions. Full details will be circulated in the coming weeks.

Latest Jobs

Principal / Senior Principal Biostatisticians (Phases II-IV & Statistical Analysis Research Centre)

Covance are currently recruiting for 3 Principal / Senior Principal Biostatisticians in two different departments.

Statistical Director for Health Technology Assessment in Biostatistics

Global pharma company Novo Nordisk are right now looking for a Statistical Director to drive the Health Technology Assessment agenda in the Biostatistical Centre of Expertise in their office just outside Copenhagen.

Statisticians and Statistical Programmers – Senior/Principal/Associate Director/Director - Oncology / Respiratory / CVRM – Early and Late Phase

Would you like to be a part of a Statistical and Programming group, who have direct strategic impact on drug development, playing a key role in getting medicines to patients?